TrophiCell
Scalable mesenchymal stromal cell therapeutics for regenerative medicine.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
* | N/A | £7.5m | Early VC |
| Total Funding | 000k | ||
Related Content
TrophiCell is a University of Liverpool spin-out company founded on a patented technology platform for harnessing the therapeutic potential of Mesenchymal Stromal Cells (MSCs). The company was incorporated on May 5, 2023. The core of TrophiCell's innovation, developed by Professor Anthony Hollander and his team, addresses the historical limitations of MSC therapies, such as scalability issues, batch-to-batch variability, and high manufacturing costs.
The company's proprietary approach enables the extensive expansion of MSCs from a single donor source while maintaining their crucial therapeutic properties, specifically their responsive trophic repair and immunomodulatory functions. This breakthrough overcomes a significant hurdle where MSCs traditionally lose their ability to differentiate after a few doublings, allowing for the large-scale production of standardized, therapeutically potent cell products. This process results in a more reliable and clinically effective therapy with the strong safety profile characteristic of natural adult MSCs.
The leadership team includes founder and Chief Scientific Officer Professor Anthony Hollander, a serial entrepreneur in stem cell therapies; CEO Dr. Karen Sullivan, a scientist and lawyer with over 20 years of experience in technology commercialization; and Helen Delahaye, who serves as Operations and Programme Management lead. TrophiCell's business model is focused on optimizing its technology platform and validating its efficacy in lead clinical indications, initially targeting osteoarthritis and late-stage liver disease. The strategy involves partnering with pharmaceutical companies and contract manufacturing organizations after successful Phase I/IIa trials to bring its therapies to market. The company received initial capital from the University of Liverpool's Enterprise Investment Fund and is seeking further investment to fund pre-clinical development.
Keywords: mesenchymal stromal cells, cell therapy, regenerative medicine, trophic repair, immunomodulation, stem cell technology, osteoarthritis, liver disease, cell manufacturing, biotechnology, Anthony Hollander, University of Liverpool spin-out, scalable therapeutics, fibrotic disease, inflammatory disease, advanced therapy medicinal products, cell-based therapies